Pfizer Launches Rimegepant to Strengthen Migraine Therapy

Pfizer has introduced Rimegepant, a calcitonin gene-related peptide treatment for migraine, marking a notable expansion of its neuroscience portfolio in India.

The company said the 75 mg orally disintegrating tablet is designed for adults who need fast and dependable relief from acute migraine attacks, especially those who do not respond well to triptans.

The tablet dissolves on the tongue, offering a practical option for patients who struggle to swallow medication during an attack.

According to Pfizer, Rimegepant delivers rapid and long-lasting relief, with effects that can extend up to 48 hours. The company added that current evidence suggests a lower risk of medication overuse headache, a concern commonly seen with several traditional migraine therapies.

Also Read: Unlocking India's Innovation Potential in Pharma

Meenakshi Nevatia, Managing Director of Pfizer India, said, “We understand the profound impact migraine can have on an individual’s ability to perform daily activities and care for loved ones. Our hope is that this breakthrough will help patients experience meaningful relief and reclaim productive days sooner.”

The arrival of Rimegepant comes at a time when India is seeing a rising demand for modern migraine solutions. With a large population experiencing recurring episodes, the launch strengthens Pfizer’s competitive position following its global acquisition of Biohaven, the company behind this class of drugs. Industry observers expect the therapy to widen treatment choices for neurologists and offer a promising option for patients who need more consistent results.

Pfizer’s latest move signals increased attention on migraine care in India, with the company aiming to address a significant unmet medical need through an accessible, easy-to-use formulation that supports better daily functioning for adults living with the condition.